Summit Financial LLC Grows Stake in Zimmer Biomet Holdings, Inc. $ZBH

Summit Financial LLC grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,151 shares of the medical equipment provider’s stock after buying an additional 227 shares during the quarter. Summit Financial LLC’s holdings in Zimmer Biomet were worth $244,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. MGO One Seven LLC lifted its stake in Zimmer Biomet by 5.1% in the fourth quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider’s stock worth $238,000 after acquiring an additional 110 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of Zimmer Biomet by 0.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider’s stock worth $2,903,000 after purchasing an additional 118 shares during the period. Curbstone Financial Management Corp lifted its position in shares of Zimmer Biomet by 3.4% in the 1st quarter. Curbstone Financial Management Corp now owns 4,266 shares of the medical equipment provider’s stock worth $483,000 after purchasing an additional 140 shares during the period. Brooklyn Investment Group boosted its stake in shares of Zimmer Biomet by 45.9% during the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after purchasing an additional 145 shares in the last quarter. Finally, Roberts Wealth Advisors LLC increased its holdings in shares of Zimmer Biomet by 0.8% in the 1st quarter. Roberts Wealth Advisors LLC now owns 18,497 shares of the medical equipment provider’s stock valued at $2,093,000 after acquiring an additional 152 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $107.3520 on Tuesday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The firm has a market cap of $21.27 billion, a PE ratio of 26.12, a PEG ratio of 2.12 and a beta of 0.68. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $116.71. The firm has a fifty day moving average of $95.82 and a 200 day moving average of $99.28.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter last year, the business earned $2.01 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.9%. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Analyst Ratings Changes

Several equities analysts have issued reports on ZBH shares. Stifel Nicolaus set a $115.00 price target on shares of Zimmer Biomet and gave the stock a “buy” rating in a report on Tuesday, May 6th. Royal Bank Of Canada upped their target price on Zimmer Biomet from $112.00 to $115.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Canaccord Genuity Group lowered their price target on Zimmer Biomet from $115.00 to $101.00 and set a “hold” rating for the company in a research report on Monday, May 12th. Evercore ISI dropped their price target on Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating on the stock in a research note on Tuesday, July 8th. Finally, Raymond James Financial raised their price objective on Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. Nine research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $111.44.

Insider Activity

In related news, insider Sang Yi sold 1,000 shares of the stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider owned 20,424 shares of the company’s stock, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.70% of the stock is owned by company insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.